Share: Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte's Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, Olumiant provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by per cent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with Olumiant showed significant improvements in the severity and extent of disease compared to placebo. In the integrated safety analysis of eight AD studies of Olumiant, there were no increases in rates for treatment-emergent adverse events, serious adverse events or serious infections with long-term Olumiant therapy compared to the placebo-controlled period. These results were presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.